Bausch Health Companies Inc. (BHC)
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
$5.89+1.55%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $2.2B
- Forward P/E
- 1.4
- 52-week range
- $4.33 – $8.00
- 52-week change
- −9.23%
- EPS (trailing)
- −$2.95
- Analyst rating
- 3.0 Hold
- Next earnings
- Oct 28, 2026
Fiscal year to Dec 2025
- Revenue
- $10.3B (+6.66%)
- Net income
- $157M
- Operating margin
- 17.7%
- Diluted EPS
- $0.42
- Free cash flow
- $1.0B
From the company’s annual report on SEC EDGAR.
About Bausch Health Companies Inc.
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, Czech Republic, Slovakia, Ukraine, Bulgaria, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Headquarters: Laval, Canada · 20,300 employees · bauschhealth.com